Mikkel S Kofoed1,2,3, Christian B Pedersen4,5,6, Mette K Schulz4,5,6, Bjarne W Kristensen5,6,7, Rasmus W Hansen4,5, Ljubo Markovic8, Bo Halle4,5,6, Frantz R Poulsen4,5,6. 1. Department of Neurosurgery, Odense University Hospital, Odense, Denmark. mikkel.seremet.kofoed@rsyd.dk. 2. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. mikkel.seremet.kofoed@rsyd.dk. 3. BRIDGE (Brain Research-Interdisciplinary Guided Excellence), Odense, Denmark. mikkel.seremet.kofoed@rsyd.dk. 4. Department of Neurosurgery, Odense University Hospital, Odense, Denmark. 5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark. 6. BRIDGE (Brain Research-Interdisciplinary Guided Excellence), Odense, Denmark. 7. Department of Pathology, Odense University Hospital, Odense, Denmark. 8. Department of Radiology, Odense University Hospital, Odense, Denmark.
Abstract
BACKGROUND: Sodium fluorescein (fluorescein) crosses a disrupted blood-brain barrier similarly to gadolinium contrast in contrast-enhancing cerebral tumors. When exposed to light with 560 nm wavelength during surgery, fluorescein emits a yellow-green fluorescent light that can be visualized through an operating microscope equipped with an appropriate emission filter. The distribution of the fluorescence correlates with the contrast on a gadolinium contrast-enhanced MRI. OBJECTIVE: The objective of this single-center retrospective study was to investigate if the use of fluorescein would increase the extent of resection and to examine if fluorescein guided resection influences postoperative neurological status. METHODS: During the study period from August 2014 to August 2018, 117 patients were operated for cerebral metastases. Of these, 56 operations were guided by fluorescein and 61 by traditional white light. All patients had an early postoperative MRI within 72 h after surgery. RESULTS: The use of fluorescein increased the extent of resection in patients with cerebral metastases. The use of fluorescein was not associated with increased postoperative sequelae or neurological damage regardless of underlying primary cancer. CONCLUSION: Fluorescein is a helpful supplement in the neurosurgical treatment of cerebral metastases.
BACKGROUND: Sodium fluorescein (fluorescein) crosses a disrupted blood-brain barrier similarly to gadolinium contrast in contrast-enhancing cerebral tumors. When exposed to light with 560 nm wavelength during surgery, fluorescein emits a yellow-green fluorescent light that can be visualized through an operating microscope equipped with an appropriate emission filter. The distribution of the fluorescence correlates with the contrast on a gadolinium contrast-enhanced MRI. OBJECTIVE: The objective of this single-center retrospective study was to investigate if the use of fluorescein would increase the extent of resection and to examine if fluorescein guided resection influences postoperative neurological status. METHODS: During the study period from August 2014 to August 2018, 117 patients were operated for cerebral metastases. Of these, 56 operations were guided by fluorescein and 61 by traditional white light. All patients had an early postoperative MRI within 72 h after surgery. RESULTS: The use of fluorescein increased the extent of resection in patients with cerebral metastases. The use of fluorescein was not associated with increased postoperative sequelae or neurological damage regardless of underlying primary cancer. CONCLUSION: Fluorescein is a helpful supplement in the neurosurgical treatment of cerebral metastases.
Authors: Lasse Cramer Ahrens; Mathias Green Krabbenhøft; Rasmus Würgler Hansen; Nikola Mikic; Christian Bonde Pedersen; Frantz Rom Poulsen; Anders Rosendal Korshoej Journal: Cancers (Basel) Date: 2022-01-26 Impact factor: 6.639